Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma

References

• Ferlay, J, Bray, F, Pisani, P, Parkin, DM. Cancer incidence, mortality and prevalence worldwide. Version 1.0. International Agency for Research on Cancer (IARC) Cancer Base no. 5. LyonFrance: IARC Press, 2001.
   Google Scholar
• Hussey DH, Latourette HB, Panje WR. Head and neck cancer: an analysis of the incidence, patterns of treatment and survival at the University of Iowa. Ann Otol Rhinol Laryngol Suppl 1991; 100(Suppl 152)2–16
   Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949–55
   PubMed Web of Science ®Google Scholar
• Pignon JP, Hill C. Meta-analysis of randomized clinical trials in oncology. Lancet Oncol 2001; 2: 475–82
   PubMed Web of Science ®Google Scholar
• Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890–9
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–8
   PubMed Web of Science ®Google Scholar
• Hinerman RW, Amdur RJ, Mendenhall WM, Villaret DB, Robbins KT. Hypopharyngeal carcinoma. Curr Treat Options Oncol 2002; 3: 41–9
   PubMedGoogle Scholar
• Prades JM, Timoshenko AP, Schmitt TH, Delolme MP, Francoz M, Martin C, et al. Planned neck dissection before combined chemoradiation for pyriform sinus carcinoma. Acta Otolaryngol 2008; 128: 324–8
   PubMed Web of Science ®Google Scholar
• Wolf GT. Commentary: phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concurrent chemotherapy and radiotherapy versus radiotherapy-intergroup trial R91-11. J Clin Oncol 2001; 19(18 Suppl)285S–31S
   Web of Science ®Google Scholar
• Prades JM, Schmitt TM, Timoshenko AP, Simon PG, de Cornulier J, Durand M, et al. Concomitant chemoradiotherapy in pyriform sinus carcinoma. Arch Otolaryngol Head Neck Surg 2002; 128: 384–8
   PubMedGoogle Scholar
• Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006; 64: 983–94
   PubMed Web of Science ®Google Scholar
• Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–71
   PubMed Web of Science ®Google Scholar
• Yoon MS, Chung WK, Ahn SJ, Nam TK, Nah BS, Song JY, et al. Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma. Acta Otolaryngol 2008; 128: 590–6
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695–704
   PubMed Web of Science ®Google Scholar
• Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, et al. Rate of pathologic complete responses to docetaxel, cisplatin and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2006; 132: 678–81
   PubMedGoogle Scholar
• Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636–45
   PubMed Web of Science ®Google Scholar
• Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P), fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000–2001. J Clin Oncol 2006; 24: 5506, (abstract)
   Web of Science ®Google Scholar
• Hitt, R, Grau, J, Lopez-Pousa, A, Berrocal, A, Garcia-Giron, C, Belon, J, , et al. Randomized phase II-III clinical trial of induction chemotherapy (IC) with either cisplatin-5-fluorouracil (PF) or docetaxel-cisplatin-5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone for patients with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2006; 24: 5515, (abstract)
   Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–78
   PubMed Web of Science ®Google Scholar
• Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 2006; 354: 634–6
   PubMed Web of Science ®Google Scholar